AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2440683 — intervention group
Group type: EXPERIMENTAL
Intervention: sotalol 1.5 mg kg‐1
Number of subjects: 12
Study 2440683 — intervention group
Group type: EXPERIMENTAL
Intervention: aprindine 1 mg kg‐1 & sotalol 0.75 mg kg‐1
Number of subjects: 12
Study 29423258 — intervention group
Group type: EXPERIMENTAL
Intervention: Social identity group management intervention delivered by COPD rehabilitation staff
Number of subjects: 0
Study 29423258 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 27412590 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromelain (1,050 mg/day)
Number of subjects: 68
Study 27412590 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch-filled capsules)
Number of subjects: 68
Study 25787199 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 months of dual antiplatelet therapy (continued thienopyridine)
Number of subjects: 11648
Study 25787199 — intervention group
Group type: COMPARATOR
Intervention: 12 months of dual antiplatelet therapy (placebo)
Number of subjects: 11648
Study 23279713 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral training
Number of subjects: 60
Study 23279713 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 20339966 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (2.5-5 mg/day)
Number of subjects: 72
Study 20339966 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 72
Study 20339966 — intervention group
Group type: COMPARATOR
Intervention: Elderly patients with stable angina pectoris (SAP) (control group)
Number of subjects: 72
Study 18489500 — intervention group
Group type: EXPERIMENTAL
Intervention: OAB-q questionnaire
Number of subjects: 398
Study 18489500 — intervention group
Group type: EXPERIMENTAL
Intervention: OAB-q HRQL subscales
Number of subjects: 398
Study 18489500 — intervention group
Group type: EXPERIMENTAL
Intervention: PPBC (patient's perception of bladder condition)
Number of subjects: 398
Study 16310303 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerec system [CHAIR]
Number of subjects: 10
Study 16310303 — intervention group
Group type: COMPARATOR
Intervention: IPS Empress system [LAB]
Number of subjects: 10
Study 16310303 — intervention group
Group type: COMPARATOR
Intervention: Cerec system [CHAIR] and IPS Empress system [LAB]
Number of subjects: 10
Study 12661198 — intervention group
Group type: EXPERIMENTAL
Intervention: Parametric adjustments to Hill-type musculo-tendon models
Number of subjects: 0
Study 10811328 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 20 mg/kg/prednisolone
Number of subjects: 24
Study 10811328 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA) 2 mg/kg/prednisolone
Number of subjects: 24
Study 8809913 — intervention group
Group type: COMPARATOR
Intervention: AHA position
Number of subjects: 20
Study 8809913 — intervention group
Group type: EXPERIMENTAL
Intervention: ERC position
Number of subjects: 20
Study 8809913 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC position
Number of subjects: 20
Study 8809913 — intervention group
Group type: EXPERIMENTAL
Intervention: Rautek's position
Number of subjects: 20
Study 1534715 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg)
Number of subjects: 0
Study 1534715 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine (20 mg)
Number of subjects: 0
Study 6201145 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES)
Number of subjects: 80
Study 6201145 — intervention group
Group type: COMPARATOR
Intervention: Plasma
Number of subjects: 80
Study 31574323 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional object version of the DCCS
Number of subjects: 0
Study 31574323 — intervention group
Group type: COMPARATOR
Intervention: Standard two-dimensional DCCS
Number of subjects: 0
Study 29402241 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive mHealth application on safe sexual health installed on smartphones
Number of subjects: 446
Study 29402241 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 446
Study 29402241 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive mHealth application
Number of subjects: 446
Study 27081187 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation for Quit Assistance
Number of subjects: 255
Study 27081187 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives
Number of subjects: 255
Study 27081187 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning about research or helping others quit
Number of subjects: 255
Study 27081187 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning about smoking and risks
Number of subjects: 255
Study 27081187 — intervention group
Group type: EXPERIMENTAL
Intervention: Quit Assistance
Number of subjects: 255
Study 24930625 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab (10mg/kg) + Dacarbazine (1000 mg/m(2)) (Arm A)
Number of subjects: 106
Study 24930625 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab only (10mg/kg) (Arm B)
Number of subjects: 106
Study 22881197 — intervention group
Group type: EXPERIMENTAL
Intervention: Camelina meal (15%)
Number of subjects: 180
Study 22881197 — intervention group
Group type: COMPARATOR
Intervention: Control diet (15% canola meal)
Number of subjects: 180
Study 22881197 — intervention group
Group type: EXPERIMENTAL
Intervention: Camelina meal (various levels)
Number of subjects: 180
Study 20967670 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric warm-up exercise
Number of subjects: 10
Study 20967670 — intervention group
Group type: COMPARATOR
Intervention: No prior exercise (control)
Number of subjects: 10
Study 17654281 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency words in Experiment 1
Number of subjects: 0
Study 17654281 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency words in Experiment 1
Number of subjects: 0
Study 17654281 — intervention group
Group type: EXPERIMENTAL
Intervention: High-imageability words in Experiment 2
Number of subjects: 0
Study 17654281 — intervention group
Group type: COMPARATOR
Intervention: Low-imageability words in Experiment 2
Number of subjects: 0
Study 16299436 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistically homogeneous results of primary randomized controlled trials (RCTs)
Number of subjects: 120
Study 16299436 — intervention group
Group type: EXPERIMENTAL
Intervention: Large overall effect size
Number of subjects: 120
Study 16299436 — intervention group
Group type: EXPERIMENTAL
Intervention: Data presented as risk difference for treatment outcome
Number of subjects: 120
Study 16299436 — intervention group
Group type: EXPERIMENTAL
Intervention: Small effect size
Number of subjects: 120
Study 11977877 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine challenge testing
Number of subjects: 105
Study 11977877 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometry
Number of subjects: 105
Study 11977877 — intervention group
Group type: EXPERIMENTAL
Intervention: Full pulmonary function testing (PFT)
Number of subjects: 105
Study 11977877 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial blood gas testing
Number of subjects: 105
Study 11977877 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest radiography (CXR)
Number of subjects: 105
Study 11977877 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory evaluation
Number of subjects: 105
Study 11977877 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac evaluation
Number of subjects: 105
Study 10067001 — intervention group
Group type: COMPARATOR
Intervention: GAD-relevant words, speech anxiety-relevant words, strongly pleasant words, and neutral valence words in the 1st experiment
Number of subjects: 122
Study 10067001 — intervention group
Group type: COMPARATOR
Intervention: Threatening words in the 2nd experiment
Number of subjects: 122
Study 8527621 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide oxide 0.5 mg
Number of subjects: 242
Study 8527621 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide oxide 1 mg
Number of subjects: 242
Study 8527621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study 2275651 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam to supplement local anaesthesia
Number of subjects: 32
Study 2275651 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthesia alone
Number of subjects: 32
Study 2275651 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 32
Study 109935 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chemotherapy (vincristine, fluorouracil, methotrexate, and thiotepa) for 3 months after adrenalectomy-oophorectomy
Number of subjects: 31
Study 109935 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy (Control group)
Number of subjects: 31
Study 109935 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chemotherapy (vincristine, fluorouracil, methotrexate, and thiotepa)
Number of subjects: 31
Study 29306475 — intervention group
Group type: EXPERIMENTAL
Intervention: Darapladib, 160mg daily
Number of subjects: 54
Study 29306475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 27756421 — intervention group
Group type: COMPARATOR
Intervention: Donepezil 10 mg QD
Number of subjects: 438
Study 27756421 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-126 25 mg QD
Number of subjects: 438
Study 27756421 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-126 50 mg QD
Number of subjects: 438
Study 27756421 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-126 75 mg QD
Number of subjects: 438
Study 25352616 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural control intervention
Number of subjects: 76
Study 25352616 — intervention group
Group type: COMPARATOR
Intervention: Manual stretching
Number of subjects: 76
Study 22955245 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral smoking cessation treatment with 8 weeks of open-label nicotine patch treatment
Number of subjects: 83
Study 20545208 — intervention group
Group type: EXPERIMENTAL
Intervention: Calming the liver and restraining the Yang formula
Number of subjects: 348
Study 20545208 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 348
Study 18375569 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral paliperidone
Number of subjects: 0
Study 18375569 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral paliperidone (doses > 3 mg/day)
Number of subjects: 0
Study 18375569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18375569 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 0
Study 16649835 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram treatment for 32 weeks
Number of subjects: 30
Study 11250997 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Breast Cancer CDROM
Number of subjects: 180
Study 11250997 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 180
Study 9602961 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg twice daily for 1 week
Number of subjects: 10
Study 9602961 — intervention group
Group type: COMPARATOR
Intervention: Control (no cimetidine)
Number of subjects: 10
Study 7992443 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ionizing device
Number of subjects: 19
Study 7992443 — intervention group
Group type: COMPARATOR
Intervention: Inactive placebo-device
Number of subjects: 19
Study 2465815 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care plus combination chemotherapy (cisplatin and vinblastine)
Number of subjects: 0
Study 2465815 — intervention group
Group type: COMPARATOR
Intervention: Supportive care (palliative radiation, psychosocial support, analgesics, nutritional support)
Number of subjects: 0
Study 2465815 — intervention group
Group type: COMPARATOR
Intervention: Supportive care
Number of subjects: 0
Study 8375679 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic resistance strength training program (12 weeks, 3 times per week using elastic tubing)
Number of subjects: 55
Study 8375679 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 55
Study 391489 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% clobetasone butyrate
Number of subjects: 40
Study 391489 — intervention group
Group type: COMPARATOR
Intervention: 0.1% hydrocortisone butyrate
Number of subjects: 40
Study 391489 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40
Study 31270176 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Heat-and-Moisture Exchanger (HME)
Number of subjects: 15
Study 27786578 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral labetalol
Number of subjects: 50
Study 27786578 — intervention group
Group type: COMPARATOR
Intervention: Oral extended release nifedipine
Number of subjects: 50
Study 25246441 — intervention group
Group type: EXPERIMENTAL
Intervention: Customised foot orthoses
Number of subjects: 140
Study 25246441 — intervention group
Group type: COMPARATOR
Intervention: Sham foot orthoses
Number of subjects: 140
Study 23026349 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi training for six months
Number of subjects: 60
Study 23026349 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control receiving unaltered usual medical care
Number of subjects: 60
Study 21726495 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide 80 mg with 240 ml of 20% glucose solution after a 10 h overnight fasting
Number of subjects: 18
Study 21726495 — intervention group
Group type: COMPARATOR
Intervention: Test products A & B
Number of subjects: 18
Study 21726495 — intervention group
Group type: COMPARATOR
Intervention: Reference product R
Number of subjects: 18
Study 19950717 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated poliomyelitis vaccine (IPV)
Number of subjects: 416
Study 19950717 — intervention group
Group type: COMPARATOR
Intervention: Oral poliomyelitis vaccine (OPV)
Number of subjects: 416
Study 17322810 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafil 3D system with .06 tapered master cone
Number of subjects: 44
Study 17322810 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafil 3D system with .02 tapered master cone
Number of subjects: 44
Study 17322810 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold lateral condensation with .06 tapered master cone
Number of subjects: 44
Study 17322810 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold lateral condensation with .02 tapered master cone
Number of subjects: 44
Study 15364319 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin with provisional GP IIb/IIIa blockade
Number of subjects: 6010
Study 15364319 — intervention group
Group type: COMPARATOR
Intervention: Heparin with routine GP IIb/IIIa blockade
Number of subjects: 6010
Study 15364319 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel pretreatment
Number of subjects: 6010
Study 11826803 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis prevention measures during childhood
Number of subjects: 0
Study 11826803 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintaining adequate levels of calcium intake, serum vitamin D, and weightbearing physical activity
Number of subjects: 0
Study 11826803 — intervention group
Group type: EXPERIMENTAL
Intervention: Creation of reference data for bone mineralization
Number of subjects: 0
Study 9661556 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with 2 micrograms/kg clonidine for ICB
Number of subjects: 36
Study 9661556 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine with saline for ICB and IM injection of saline (Control group)
Number of subjects: 36
Study 9661556 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with saline for ICB and IM injection of 2 micrograms/kg clonidine (IM group)
Number of subjects: 36
Study 7662226 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg verapamil
Number of subjects: 186
Study 7662226 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg enalapril
Number of subjects: 186
Study 7662226 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg verapamil + 10 mg enalapril
Number of subjects: 186
Study 7662226 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg verapamil + 10 mg enalapril
Number of subjects: 186
Study 7662226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 7662226 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 186
Study 2569239 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 67
Study 2569239 — intervention group
Group type: COMPARATOR
Intervention: Loprazolam 1 mg
Number of subjects: 67
Study 2569239 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred treatment (either triazolam or loprazolam)
Number of subjects: 67
Study 772175 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (26 mg daily for 12 weeks)
Number of subjects: 31
Study 772175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 30569761 — intervention group
Group type: EXPERIMENTAL
Intervention: Block Periodization (BLOCK)
Number of subjects: 47
Study 30569761 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Undulating Periodization (DUP)
Number of subjects: 47
Study 28209488 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (n=40)
Number of subjects: 80
Study 28209488 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=40)
Number of subjects: 80
Study 26468834 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied with GaAlAs, 830 nm wavelength, power of 40 mW, energy of 8.4 J/cm2 dose per spot, applied in 8 treatment sessions at 48-hour intervals
Number of subjects: 9
Study 26468834 — intervention group
Group type: COMPARATOR
Intervention: Control group (no laser therapy)
Number of subjects: 9
Study 23481125 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavones (250 mg of standardized soy extract corresponding to isoflavone 100 mg/day)
Number of subjects: 80
Study 23481125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 20959525 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium 200 µg
Number of subjects: 272
Study 20959525 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium 800 µg
Number of subjects: 272
Study 20959525 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 272
Study 20959525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study 19946430 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic screening for AAA
Number of subjects: 4
Study 17048062 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk basic protein (MBP) 40 mg per day
Number of subjects: 35
Study 17048062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 14732661 — intervention group
Group type: COMPARATOR
Intervention: Skin self‐examination without photography
Number of subjects: 50
Study 14732661 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin self‐examination with photography
Number of subjects: 50
Study 12025949 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg daily
Number of subjects: 20
Study 12025949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9669245 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 2141
Study 9669245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2141
Study 7809577 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (0.4 mg/kg body weight as an intravenous bolus followed by continuous infusion of 0.4 mg/kg/h for 6 hours)
Number of subjects: 52
Study 7809577 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin + light hypoxia
Number of subjects: 52
Study 7809577 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin + hypercapnia
Number of subjects: 52
Study 7809577 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypoxia (FiO2 13%)
Number of subjects: 52
Study 7809577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 3292590 — intervention group
Group type: EXPERIMENTAL
Intervention: Regulated-breathing method (treatment)
Number of subjects: 32
Study 3292590 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 32
Study 30223773 — intervention group
Group type: EXPERIMENTAL
Intervention: Repositioning the R‐DLT into the left main bronchus (Group L)
Number of subjects: 60
Study 30223773 — intervention group
Group type: COMPARATOR
Intervention: Repositioning the R‐DLT into the right main bronchus (Group R)
Number of subjects: 60
Study 30223773 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of lung collapse during one‐lung ventilation (Group L)
Number of subjects: 60
Study 30223773 — intervention group
Group type: COMPARATOR
Intervention: Bronchial injuries (Group R)
Number of subjects: 60
Study 30223773 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial injuries (Group L)
Number of subjects: 60
Study 30223773 — intervention group
Group type: COMPARATOR
Intervention: Vocal cord injuries (Group R)
Number of subjects: 60
Study 30223773 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal cord injuries (Group L)
Number of subjects: 60
Study 27982270 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 16
Study 27982270 — intervention group
Group type: COMPARATOR
Intervention: Pyridostigmine
Number of subjects: 16
Study 25529060 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency (ID) patients at ICU discharge
Number of subjects: 107
Study 25529060 — intervention group
Group type: COMPARATOR
Intervention: Non-ID patients at ICU discharge
Number of subjects: 107
Study 25529060 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients at D28
Number of subjects: 107
Study 25529060 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients at M6
Number of subjects: 107
Study 23782092 — intervention group
Group type: EXPERIMENTAL
Intervention: Board game
Number of subjects: 120
Study 23782092 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture
Number of subjects: 120
Study 20728932 — intervention group
Group type: EXPERIMENTAL
Intervention: HEV 239 vaccine (30 microg of purified recombinant hepatitis E antigen adsorbed to 0.8 mg aluminium hydroxide suspended in 0.5 mL buffered saline)
Number of subjects: 56302